Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
European Urology|June 16, 2012
Active surveillance for prostate cancer: a systematic review of the literatureMarc A Dall'Era, Peter C Albertsen, Christopher Bangma, et al.
BJU International|September 12, 2024
Differences in mutations across tumour sizes in clear-cell renal cell carcinomaSteven M Monda, Benjamin W Carney, Allison M May, et al.
Cancer|March 29, 2016
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancerHelen Chow, Paramita M Ghosh, Ralph deVere White, et al.
Cancer|April 25, 2008
Active surveillance for the management of prostate cancer in a contemporary cohortMarc A Dall'Era, Badrinath R Konety, Janet E Cowan, et al.
Cancer Medicine|October 29, 2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy eraIsaac E Kim, Thomas L Jang, Sinae Kim, et al.
Nanomedicine (London, England)|June 2, 2026
A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancerAthira Narayan, Ryan C Leibrandt, Joyce S Lee, et al.
Cancer|February 29, 2008
Active surveillance for early-stage prostate cancer: review of the current literatureMarc A Dall'Era, Matthew R Cooperberg, June M Chan, et al.
Urologic Oncology|March 13, 2024
Alignment of molecular subtypes across multiple bladder cancer subtyping classifiersMoritz J Reike, Joep J de Jong, Tarek A Bismar, et al.
European Urology|May 27, 2019
The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus StatementMatthew R Cooperberg, Peter R Carroll, Marc A Dall'Era, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2024
Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogrammingYatian Yang, Xiong Zhang, Demin Cai, et al.
Pageof 7